{
    "name": "crisaborole topical",
    "comment": "Rx",
    "other_names": [
        "Eucrisa"
    ],
    "classes": [
        "PDE-4 Inhibitors",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/eucrisa-crisaborole-topical-1000106",
    "pregnancy": {
        "common": [
            "Available data from case reports with use in pregnant women are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes",
            "Crisaborole is systemically absorbed"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "No adverse developmental effects observed in animal reproduction studies, with oral administration of this drug in pregnant rats and rabbits during organogenesis at doses up to 3 and 2 times, respectively, the maximum recommended human dose (MRHD)"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Crisaborole is systemically absorbed",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of hypersensitivity to crisaborole or any component of the formulation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions reported, including contact urticaria; signs and symptoms may include severe pruritus, swelling, and erythema at the application site or at a distant site; discontinue immediately and initiate appropriate therapy if hypersensitivity suspected (see Contraindications)"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Application site pain",
            "percent": "4"
        },
        {
            "name": "burning",
            "percent": null
        },
        {
            "name": "or stinging",
            "percent": null
        },
        {
            "name": "Contact urticaria",
            "percent": null
        },
        {
            "name": "Allergic contact dermatitis",
            "percent": null
        }
    ]
}